RDY - Dr. Reddy’s Laboratories Ltd ADR
Exchange: USA Stocks • Country: India • Currency: USD • Type: Common Stock • ISIN: US2561352038
Generic Medicines, Active Pharmaceutical Ingredients, Biologics
Dr. Reddy's Laboratories Limited is a global pharmaceutical company that operates through three main segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others.
The Global Generics segment is responsible for manufacturing and marketing a wide range of prescription and over-the-counter pharmaceutical products, including branded and generic finished dosages that are therapeutically equivalent to branded formulations. This segment also includes the company's biologics business, which involves the development and production of complex biological molecules used to treat various diseases.
The PSAI segment is focused on manufacturing and marketing active pharmaceutical ingredients (APIs) and intermediates, which are essential components used in the production of finished pharmaceutical products. This segment also provides contract research services, where the company collaborates with clients to develop and manufacture APIs and steroids according to their specific requirements.
The Others segment is involved in developing innovative therapies in areas such as oncology and inflammation, as well as researching and developing differentiated formulations that can improve patient outcomes. This segment also provides digital healthcare and information technology-enabled business support services, which help to streamline healthcare operations and improve patient care.
Dr. Reddy's Laboratories offers a diverse range of products that cater to various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. With a strong presence in over 25 countries, the company is committed to providing affordable and innovative healthcare solutions to patients around the world.
Founded in 1984, Dr. Reddy's Laboratories is headquartered in Hyderabad, India, and has established itself as a leading player in the global pharmaceutical industry. For more information, please visit the company's website at https://www.drreddys.com.
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for RDY - Dr. Reddy’s Laboratories Ltd ADR](https://www.valueray.com/images/drawdown_chart/RDY.NYSE_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for RDY - Dr. Reddy’s Laboratories Ltd ADR](https://www.valueray.com/images/chart/RDY.NYSE_seasonality.png)
RDY Stock Overview
Market Cap in USD | 13,562m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 2001-04-11 |
RDY Stock Ratings
Growth 5y | 59.0 |
Fundamental | 54.4 |
Dividend | 52.7 |
Rel. Performance vs Sector | 0.67 |
Analysts | 3.00/5 |
Fair Price Momentum | 81.49 USD |
Fair Price DCF | 2848.93 USD |
RDY Dividends
Dividend Yield 12m | 0.59% |
Yield on Cost 5y | 1.33% |
Dividends CAGR 5y | 28.02% |
Payout Consistency | 93.9% |
RDY Growth Ratios
Growth 12m | 18.75% |
Growth Correlation 12m | 42% |
Growth Correlation 3m | 54% |
CAGR 5y | 17.57% |
CAGR/Mean DD 5y | 1.42 |
Sharpe Ratio 12m | 0.67 |
Alpha vs SP500 12m | 5.77 |
Beta vs SP500 5y weekly | 0.49 |
ValueRay RSI | 83.75 |
Volatility GJR Garch 1y | 21.31% |
Price / SMA 50 | 10.53% |
Price / SMA 200 | 14.43% |
Current Volume | 250.3k |
Average Volume 20d | 249.8k |
External Links for RDY Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of July 27, 2024, the stock is trading at USD 81.22 with a total of 250,264 shares traded.
Over the past week, the price has changed by +3.97%, over one month by +13.44%, over three months by +9.61% and over the past year by +18.97%.
According to ValueRays Forecast Model, RDY Dr. Reddy’s Laboratories Ltd ADR will be worth about 88 in July 2025. The stock is currently trading at 81.22. This means that the stock has a potential upside of +8.36%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 80.2 | -1.32 |
Analysts Target Price | 70.1 | -13.7 |
ValueRay Target Price | 88 | 8.36 |